Henagliflozin's Impact on Prediabetes Remission

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 984 participants.

Also called NCT06448130

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 984 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06448130
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06448130. Randomized; quadruple masking; primary purpose treatment. Start 2024-06 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Henagliflozin's Impact on Prediabetes Remission
Condition
PreDiabetes
Condition
Prediabetic State
Condition
Glucose Metabolism Disorders
Intervention (Drug)
Henagliflozin 5mg
Intervention (Drug)
Henagliflozin 10mg
Intervention (Drug)
Placebo
Lead sponsor
Shandong Provincial Hospital (class: other government)

Record details

Record id
cardio:ct-nct06448130
Content hash
29fb5ef895bf1ee7e5dac4648320ad784a18f88fe3a659291e4f1086039283ea